Rebecca Robbins

The Trump administration said that had the new prices been in effect last year, Medicare would have saved $12 billion, which would have reduced its spending on those drugs by 44 percent.

The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.

Dr. Richard Pazdur, who has been the F.D.A.’s top cancer drug regulator, represents a stabilizing choice for an agency reeling under staff cuts and low morale.

President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

President Trump wants pharmaceutical production to return to the United States. A shuttered factory in Louisiana shows how hard that will be for generic medicines.

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.

The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.

The owner of Kleenex and Huggies will acquire the company that has fought unproven claims by the Trump administration that a common pain reliever is linked to autism.

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may help lower drug costs.